Jinyang Cai, Sheeba Jacob, Richard Kurupi, Krista M Dalton, Colin Coon, Patricia Greninger, Regina K Egan, Giovanna T Stein, Ellen Murchie, Joseph McClanaghan, et al. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell reports. 2022. 40. 4. 111095-111095
Wenjing Su, Radha Mukherjee, Rona Yaeger, Jieun Son, Jianing Xu, Na Na, Neilawattie Merna Timaul, Jaclyn Hechtman, Viktoriya Paroder, Mika Lin, et al. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular cell. 2022. 82. 13. 2443-2457
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Hiromichi Ebi. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Cancers. 2021. 13. 20
Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zea Tan, Rui Yamaguchi, Hiromichi Ebi. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. 26. 22. 5962-5973
Akihiro Nishiyama, Shinji Takeuchi, Yuta Adachi, Sakiko Otani, Azusa Tanimoto, Motoko Sasaki, Shingo Matsumoto, Koichi Goto, Seiji Yano. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Cancer science. 2020. 111. 10. 3813-3823
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Akihiro Nishiyama, Azusa Tanimoto, Yuta Adachi, Shinji Takeuchi, Hiroyuki Yamaguchi, Minoru Fukuda, et al. AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells. CANCER RESEARCH. 2019. 79. 13
谷口 寛和, 山田 忠明, 王 融, 谷村 恵子, 足立 雄太, 西山 明宏, 谷本 梓, 竹内 伸司, 山口 博之, 高山 浩一, et al. オシメルチニブに対する初期耐性と治療抵抗性細胞の出現へのAXLの関与(AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells). 日本癌学会総会記事. 2018. 77回. 185-185
